Veracyte (VCYT) is back on investor radar after raising its 2026 revenue outlook and reporting second quarter results that turned a prior net loss into net income, supported by new cancer diagnostics launches.

The raised 2026 revenue outlook and strong second quarter earnings have been followed by a sharp pullback, with Veracyte’s share price down 22.5% over one day and 18.9% over 30 days. However, the 90 day share price return of 40.0% and one year total shareholder return of 95.9% still point to strong longer term momentum.

If this kind of cancer diagnostics story has caught your attention, it can also be useful to look across the sector and see what else is moving through 41 healthcare AI stocks

Veracyte’s jump in earnings, raised 2026 outlook and then sudden pullback present a clear fork in the road. Is this a chance to start a position after the drop, or a moment to wait until the valuation cools further?

Most Popular Narrative: 18.1% Undervalued

At a last close of $46.32 against a narrative fair value of $56.55, Veracyte is framed as undervalued, with that gap hinging on its cancer testing pipeline and earnings profile.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Curious what sits behind that valuation gap for Veracyte. The narrative leans on compound revenue growth, steady margins, and a rich earnings multiple that assumes sustained adoption.

Result: Fair Value of $56.55 (UNDERVALUED)

However, Veracyte’s reliance on Afirma and Decipher, along with ongoing reimbursement and regulatory pressures, could quickly challenge the current growth and valuation narrative.

Another View On Veracyte’s Valuation

The first narrative frames Veracyte as 18.1% undervalued using a fair value of $56.55. On earnings multiples, the picture is more cautious. Veracyte trades on a P/E of 32.3x, while the fair ratio is 19.7x and the US Biotechs industry sits at 17.1x.

Peer companies on average trade at 52.2x, so Veracyte sits between a richer industry tag and a lower fair ratio that the market could move toward over time. That gap highlights valuation risk if expectations ease, and it can also provide some support if investors continue to pay a premium for growth. Which side of that trade-off are you more comfortable with right now?

Next Steps

With both risks and rewards in play for Veracyte, it makes sense to move quickly and weigh the full picture yourself. To see the balance of concerns and potential upsides in context, check out the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Veracyte?

If Veracyte has sharpened your focus on opportunities, do not stop here. Broaden your watchlist and give yourself more options before the next move.

• Target potential mispricings by reviewing companies flagged as high quality and trading below their assessed value through 55 high quality undervalued stocks.
• Strengthen your focus on resilience by scanning stocks with healthier balance sheets and solid fundamentals using solid balance sheet and fundamentals stocks screener (45 results).
• Spot under-the-radar opportunities by checking screener containing 19 high quality undiscovered gems that most investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.